Navigation Links
Study shows large-scale genomic testing feasible, impacts therapy
Date:11/15/2012

DENVER Targeted cancer therapy has been transforming the care of patients with non-small-cell lung cancer (NSCLC). It is now standard practice for tumor specimens from NSCLC patients to be examined for EGFR mutations and ALK rearrangements to identify patients for therapy with EGFR and ALK inhibitors, respectively. Now, researchers say large-scale genomic testing is feasible within the clinical workflow, impacting therapeutic decisions. The study is published in the December 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology.

Researchers from the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute, in conjunction with the Center for Advanced Molecular Diagnostics in the Pathology Department at the Brigham and Women's Hospital and the Laboratory for Molecular Medicine at the Partners Healthcare Center for Personalized Genetic Medicine, introduced prospective genotyping of advanced NSCLC for somatic alterations in BRAF, HER2, PIK3CA, and ALK in July 2009, in addition to routine mutational analysis of EGFR and KRAS, which had been ongoing since 2004. Three-hundred forty-four specimens taken from 419 patients were successfully genotyped with a median turnaround time of 31 days.

"The goals of the genomic characterization of our NSCLC patients are to help guide therapy and ultimately lead to improved outcomes for those patients with specific genomic changes," the authors say. "As the repertoire of mutations for which targeted therapy may be offered expands in lung cancer and other solid malignancies, strategies to enable rapid, accurate and comprehensive clinical genotyping will be essential to successfully integrate tumor molecular analysis into the fast pace of clinical decision making and yield its greatest potential impact on patient management."


'/>"/>

Contact: Kristal Griffith
Kristal.Griffith@iaslc.org
720-325-2952
International Association for the Study of Lung Cancer
Source:Eurekalert

Page: 1

Related medicine news :

1. Study shows bone metastases treatment can improve overall survival
2. Authors of landmark study on infant mortality and electronic medical records receive Garfield Award
3. Study Tracks Brain Gene Response to Territorial Aggression
4. Study shows different approach after progression in non-small cell lung cancer patients
5. Study reveals insights that could aid in therapeutic use of mesenchymal stem cells
6. Alcoholic Drinks Add 100 Calories a Day to Average Adults Diet: Study
7. Cash cuts increase smoking death risk for worlds poor, study says
8. Study finds asthma is not linked to lower educational attainment
9. RSV study shows potential for vaccine strategies to protect babies
10. Lyme Rash Reappearance Probably Signals New Infection, Study Says
11. Study finds reformulated ER Oxycodone abuse rates are significantly lower than original ER Oxycodone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... 23, 2017 , ... “Some Infallible Characteristics of Christ”: a fascinating and ... Christ” is the creation of published author, Rev. Dr. Robert W. Thomas, the third ... a preacher for over nineteen, a pastor for over fifteen years. He is a ...
(Date:1/22/2017)... TX (PRWEB) , ... January 22, 2017 , ... ... provide slow results. Often the results of a simple test will take days to ... Any Lab Test Now offers customers direct access to their lab tests, bypassing the ...
(Date:1/21/2017)... ... ... Phytocéane invites you to take an exotic journey deep into ... ZANZIBAR SHOWER GEL. Inspired by the beauty of Zanzibar, a Tanzanian archipelago off the ... coral to create this gentle, crystal-clear shower gel to cleanse the body and promote ...
(Date:1/21/2017)... ... January 21, 2017 , ... The Nobel Biocare™ dental ... in media for its creos™ line of bone regenerative products. Specifically, the ... which he utilizes creos™ allo.gain™ bone graft for a variety of bone reconstruction ...
(Date:1/20/2017)... ... 20, 2017 , ... Doctor C LLC, a company based out of Arizona ... to continue the marketing and distribution of its product, The Right C. , The ... better absorption than traditional vitamin C supplements. At the trade show, Doctor C had ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... The global  anxiety disorders and depression treatment market  is ... incidence of depression worldwide is anticipated to drive the market growth in the ... demand for antidepressants in the recent years. Continue ... ... ...
(Date:1/23/2017)... 23 janvier 2017  ResMed (NYSE : RMD), BMC (Pékin, ... ont annoncé aujourd,hui qu,ils se sont mis d,accord sur ... les parties. BMC et 3B seront autorisés à vendre ... à ResMed, et ResMed effectuera le paiement de la ... le litige de Floride entre les deux parties. Le ...
(Date:1/23/2017)... DIEGO , 23. Januar 2017  ResMed (NYSE: ... ) und 3B Medical ( Winter Haven, ... auf eine Vereinbarung über die Beilegung aller globalen Rechtsstreitigkeiten ... der Verkauf ihrer bestehenden Produkte im Tausch ... einmalige Zahlung an 3B leisten, um das in ...
Breaking Medicine Technology: